Table 1 Subject characteristics
From: Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease
Without NAFLD | With NAFLD | |||||
|---|---|---|---|---|---|---|
Variables | Total | Non-CAD | CAD | Total | Non-CAD | CAD |
N = 183 | N = 47 | N = 136 | N = 70 | N = 27 | N = 43 | |
Sex(Male/Female) | 121/62 | 23/24 | 98/38 | 43/27 | 16/11 | 27/16 |
Age, years | 67.2 ± 10.0 | 64.6 ± 9.9 | 68.2 ± 9.9* | 63.9 ± 9.9# | 61.3 ± 7.7 | 65.5 ± 10.9 |
Body mass index, kg/m2 | 23.9 ± 3.1 | 24.0 ± 3.5 | 23.9 ± 2.9 | 26.5 ± 3.7## | 26.5 ± 4.9 | 26.5 ± 2.8 |
Waist circumference, cm | 88.4 ± 9.3 | 86.7 ± 9.8 | 88.9 ± 9.0 | 95.4 ± 9.3## | 96.6 ± 11.7 | 94.7 ± 7.6 |
Systolic blood pressure, mmHg | 130.0 | 130.0 | 130.0 | 140.0 | 140.0 | 140.0 |
(120.0-148.0) | (119.0-150.0) | (120.0-147.8) | (128.8-151.5)# | (120.0-150.0) | (130.0-153.0) | |
Diastolic blood pressure, mmHg | 80.0 | 80.0 | 80.0 | 80.0 | 80.0 | 80.0 |
(70.0-80.0) | (70.0-85.0) | (70.0-80.0) | (71.8-90.0)## | (70.0-85.0) | (72.0-90.0) | |
Fasting plasma glucose, mmol/L | 5.3(4.9-6.1) | 5.3(5.0-5.9) | 5.3(4.9-6.1) | 5.8(5.2-7.2)## | 5.6(5.1-6.6) | 5.9(5.4-7.7) |
2 h postprandial glucose, mmol/L | 7.9(6.4-10.7) | 7.5(6.1-9.3) | 8.0(6.5-11.5)* | 10.4(8.2-12.9)## | 9.7(7.9-12.9) | 11.3(8.2-12.9) |
HbA1c,% | 6.1(5.7-6.5) | 5.9(5.6-6.3) | 6.2(5.8-6.6) | 6.5(5.9-7.6)## | 6.3(5.7-7.1) | 6.6(6.2-7.9) |
HOMA-IR | 3.8(2.4-5.3) | 3.7(2.4-5.4) | 3.9(2.4-5.3) | 6.0(3.7-7.2)## | 5.9(3.7-6.4) | 6.6(3.7-9.2) |
Total cholesterol, mmol/L | 4.3 ± 1.0 | 4.6 ± 1.1 | 4.2 ± 1.0* | 4.7 ± 1.3# | 4.5 ± 1.4 | 4.8 ± 1.2 |
Triglyceride, mmol/L | 1.4(1.0-1.9) | 1.4(0.9-2.0) | 1.4(1.0-1.8) | 2.2(1.4-3.1)## | 1.7(1.3-2.4) | 2.6(1.6-3.7)* |
HDL-c, mmol/L | 1.1 ± 0.3 | 1.2 ± 0.3 | 1.1 ± 0.3* | 1.0 ± 0.3## | 1.0 ± 0.3 | 1.0 ± 0.3 |
LDL-c, mmol/L | 2.9 ± 1.0 | 3.0 ± 0.9 | 2.9 ± 1.0 | 3.1 ± 1.0 | 3.1 ± 1.0 | 3.2 ± 1.0 |
C-reactive protein, mg/L | 1.2(0.5-3.1) | 1.0(0.4-3.0) | 1.2(0.5-3.3) | 2.3(1.0-6.9)## | 1.6(0.7-6.3) | 2.5(1.1-7.6) |
FGF21, pg/mL | 273.3 | 256.1 | 277.8 | 388.0 | 321.5 | 415.5 |
(164.9-383.7) | (150.6-351.9) | (171.1-406.6)* | (253.0-655.4)## | (239.1-497.6) | (258.0-693.7)* | |
Smoker n (%) | 82(44.8) | 16(34.0) | 66(48.5) | 31(44.3) | 12(44.4) | 19(44.2) |
Metabolic syndrome and its components | ||||||
Abdominal obesity n (%) | 93(50.8) | 22(46.8) | 71(52.2) | 55(78.6)## | 21(77.8) | 34(79.1) |
Hypertriglyceridemia n (%) | 87(47.5) | 20(42.6) | 67(49.3) | 50(71.4)## | 14(51.9) | 36(83.7)** |
Low HDL-c n (%) | 73(39.9) | 15(31.9) | 58(42.6) | 41(58.6)# | 14(51.9) | 27(62.8) |
Hypertension n (%) | 160(87.4) | 41(87.2) | 119(87.5) | 63(90.0) | 23(85.2) | 40(93.0) |
Hyperglycemia n (%) | 105(57.4) | 25(53.2) | 80(58.8) | 56(80.0)## | 21(77.8) | 35(81.4) |
Metabolic syndrome n (%) | 105(57.4) | 24(51.1) | 81(59.6) | 63(90.0)## | 23(85.2) | 40(93.0) |
Dyslipidemia n (%) | 142(77.6) | 34(72.3) | 108(79.4) | 68(97.1)## | 25(92.6) | 43(100.0) |